Patents by Inventor Marion de Jong Hendriks

Marion de Jong Hendriks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
    Patent number: 11612667
    Abstract: The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: March 28, 2023
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
  • Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer
    Publication number: 20220008568
    Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.
    Type: Application
    Filed: July 23, 2021
    Publication date: January 13, 2022
    Applicant: Advanced Accelerator Applications International SA
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
  • Enhanced in Vivo Targeting of Site-Specific Drugs
    Publication number: 20220008565
    Abstract: The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
    Type: Application
    Filed: September 24, 2021
    Publication date: January 13, 2022
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
  • Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer
    Publication number: 20210346529
    Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.
    Type: Application
    Filed: July 23, 2021
    Publication date: November 11, 2021
    Applicant: Advanced Accelerator Applications International SA
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
  • Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer
    Publication number: 20210346528
    Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.
    Type: Application
    Filed: July 23, 2021
    Publication date: November 11, 2021
    Applicant: Advanced Accelerator Applications International SA
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
  • Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer
    Patent number: 11083805
    Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: August 10, 2021
    Assignee: Advanced Accelerator Applications International SA
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
  • Enhanced in Vivo Targeting of Radiolabelled Peptides With the Means of Enzyme Inhibitors
    Publication number: 20200121813
    Abstract: The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
    Type: Application
    Filed: October 21, 2019
    Publication date: April 23, 2020
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
  • Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer
    Publication number: 20200009276
    Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.
    Type: Application
    Filed: September 24, 2019
    Publication date: January 9, 2020
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
  • Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
    Patent number: 10449260
    Abstract: The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: October 22, 2019
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
  • Radiolabeled GRPR-Antagonists For Diagnostic Imaging and Treatment of GRPR-Positive Cancer
    Publication number: 20180133349
    Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.
    Type: Application
    Filed: November 20, 2017
    Publication date: May 17, 2018
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
  • Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer
    Patent number: 9839703
    Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: December 12, 2017
    Assignee: Advanced Accelerator Applications USA, Inc.
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
  • GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER
    Publication number: 20150265732
    Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.
    Type: Application
    Filed: April 3, 2014
    Publication date: September 24, 2015
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
  • Enhanced in vivo Targeting of Radiolabelled Peptides with the Means of Enzyme Inhibitors
    Publication number: 20150104381
    Abstract: The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
    Type: Application
    Filed: July 6, 2012
    Publication date: April 16, 2015
    Applicant: BioSynthema Inc.
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks